Murdo Gordon appointed Executive Vice President and Chief Commercial Officer, BMS
![](/46/pdcnewsitem/04/13/88/BMS.jpg)
He will lead the company's Worldwide Markets in addition to a new Worldwide Commercialization team.
Bristol-Myers Squibb (BMS) has announced that Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly created position, effective 21 June 2016. Gordon will be responsible for leading the execution of commercial strategy across geographies. In this role, he will lead the company's Worldwide Markets in addition to a new Worldwide Commercialization team. Gordon will continue to report to Giovanni Caforio, CEO, and remain a member of his Leadership Team. Gordon most recently co-led the commercial organization as Head of Worldwide Markets.
“Murdo has demonstrated tremendous success driving commercial excellence at BMS, and built strong relationships with our markets across the world,” said Caforio. “Murdo has made significant contributions to our success in immuno-oncology and Eliquis, and I am confident his leadership will help drive continued growth and deliver our medicines to more patients faster.”
Gordon joined BMS in 1989 and spent the first 14 years at the company in Canada where he held positions of increasing responsibility in sales and marketing. Gordon moved into the company’s US operations in 2003 where he held senior commercial leadership positions in cardiovascular, neuroscience and market access. He led strategy and commercial operations as senior vice president for US oncology and immunoscience from 2011 to 2013, and served as president, US from 2013 to 2015. Murdo is a member of the Board of Directors of RWJBarnabas Health and received a BSc in Cell and Molecular Biology from Concordia University, Montreal, and also attended the General Management Program, CEDEP at INSEAD, Fontainebleau, France.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance